این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Diabetes and Obesity، جلد ۱۶، شماره ۴، صفحات ۲۱۳-۲۲۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Evaluation of the Effects of Empagliflozin on Serum Levels of Triglycerides and Cholesterol in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia: A Prospective Study
چکیده انگلیسی مقاله Objective: Sodium-glucose cotransporter -2 (SGLT2) inhibitors may improve lipid panels in addition to lowering blood sugar. This research examined how empagliflozin, an SGLT2 inhibitor, affected triglycerides in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia.
Materials and Methods: This prospective study was conducted at the Endocrinology Clinic of Shahid Rahimi Hospital in Khorramabad, Iran, in 2020. Thirty-eight patients were included using convenient sampling. The patients’ information including age, gender, body mass index (BMI), Fasting Blood Sugar (FBS), Hemoglobin A1c (HbA1c), 2-hour postprandial blood sugar, serum triglyceride, total cholesterol, High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), serum insulin level, serum creatinine Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Blood pressure, and urine albumin before and three months after receiving empagliflozin 10mg tablets were collected from the clinic medical archives and compared using paired t-test in SPSS software version 22.
Results: BMI, microalbuminuria, BUN, FBS, 2-hour postprandial blood sugar, and HbA1c were improved significantly (P< 0.05) after treatment with empagliflozin. In terms of lipid panels, triglyceride, cholesterol, and LDL levels were improved significantly after treatment with empagliflozin (P< 0.05). HDL levels increased following the treatment but the difference was not statistically significant. There was no linear correlation between HbA1c and HDL (P= 0.183) or triglyceride (P= 0.947) levels.
Conclusion: Empagliflozin improves triglycerides and cholesterol levels in patients with T2DM in addition to its antihyperglycemic effects. It also reduces BMI, blood pressure, BUN, and microalbuminuria.
 
کلیدواژه‌های انگلیسی مقاله Type 2 Diabetes mellitus, Dyslipidemia, Sodium-glucose co-transporter 2 inhibitor, empagliflozin
نویسندگان مقاله | Saeid Choobkar
Department of Internal Medicine, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.


| Mohsen Alilou
Department of Internal Medicine, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.


| Golnaz Mahmoudvand
Universal Scientific and Research Network (USERN), Lorestan University of Medical Sciences, Khorramabad, Iran.


| Arian Karimi Rouzbahani
Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. Surgery Education and Researching Network (SERGN), Universal Scientific and Research Network (USERN), Khorramabad, Iran.
نشانی اینترنتی http://ijdo.ssu.ac.ir/browse.php?a_code=A-10-30-426&slc_lang=en&sid=1
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده تخصصی
نوع مقاله منتشر شده پژوهشی
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات